What Is Considered an Undetectable PSA Level?

An undetectable PSA level generally means a reading below the lowest concentration your lab’s test can reliably measure, and that threshold varies depending on the assay. Standard PSA tests report results as “undetectable” when the value falls below about 0.1 ng/mL, while ultrasensitive assays push that floor down to 0.01 or even 0.005 ng/mL. The distinction matters because your doctor’s interpretation of a post-treatment PSA depends heavily on which test was used, what treatment you received, and how quickly the number is changing over time.

The Number Depends on the Test

PSA blood tests are not all built the same way. A standard clinical assay typically has a detection limit around 0.1 ng/mL, meaning any concentration below that threshold gets reported as “undetectable” or simply “<0.1." Ultrasensitive PSA assays, sometimes called third-generation assays, can measure concentrations as low as 0.01 ng/mL or lower. One widely cited study defined an undetectable ultrasensitive PSA as 0.05 ng/mL or below.[mfn]PubMed Central. Prognostic Implications of an Undetectable Ultrasensitive Prostate-Specific Antigen Level after Radical Prostatectomy[/mfn] A systematic review of ultrasensitive testing found that reaching an undetectable nadir above 0.01 ng/mL after radical prostatectomy warranted further monitoring and consideration of other risk factors, while a truly undetectable nadir conferred a low risk of recurrence.¹

The practical takeaway is that “undetectable” is not a single universal number. If your lab report says your PSA is undetectable, it means the result fell below whatever floor that particular instrument can detect. Asking your doctor which assay was used, and what its lower limit is, gives you a much clearer picture of what that result actually means.

How PSA Clears from Your Blood After Surgery

After a radical prostatectomy, the prostate is physically removed. PSA already circulating in the bloodstream does not vanish instantly. It clears in two phases. There is an initial rapid drop lasting a few hours, followed by a slower decline over days. Research measuring this clearance has found that free PSA has a terminal half-life of roughly 14 hours, while PSA bound to proteins in the blood clears much more slowly, dropping at a rate of about 0.8 ng/mL per day.² Another study found the terminal half-life of total PSA to be around 2.7 days.³

Because of this two-phase clearance, doctors wait several weeks before checking your first post-surgical PSA. One study found that all patients whose PSA followed a simple one-phase decline reached undetectable levels by day 28, while patients whose PSA showed a slower two-component decline took considerably longer.⁴ A PSA that remains detectable at 0.1 ng/mL or above at six weeks after surgery is considered persistently elevated and raises the likelihood of future recurrence.⁵ So if you are checking results at your first follow-up appointment, an undetectable reading at that point is a good sign that the surgery removed all measurable PSA-producing tissue.

Undetectable PSA After Radiation Is a Different Story

If you were treated with radiation rather than surgery, the meaning of “undetectable” shifts. Radiation kills prostate cancer cells, but the prostate gland itself usually remains in place, and healthy prostate tissue continues producing PSA. Your PSA does not drop to zero. Instead, it drifts downward over months to what is called a nadir, the lowest point it reaches before stabilizing or rising again.

The nadir after radiation varies from person to person. One large study found a median nadir of 0.6 ng/mL, with patients who stayed free of recurrence typically reaching a lower nadir of about 0.4 ng/mL compared to 1.0 ng/mL in patients who later failed.⁶ Patients who reached a nadir of 0.5 ng/mL or below and did so more than two years after treatment had better than a 90% chance of remaining failure-free at five years. A lower nadir and a longer time to reach it were both independently associated with better survival.⁷

For patients who received radiation combined with hormone therapy, the bar is even lower. A recent study found that patients whose PSA was 0.1 ng/mL or below at six months had substantially lower rates of prostate cancer death compared to those with higher readings. The risk roughly tripled for men with PSA between 0.1 and 0.2 ng/mL and rose nearly sevenfold for those above 0.5 ng/mL.⁸ So after radiation plus hormones, getting below 0.1 ng/mL is the goal, even though the prostate gland is still there.

When a Rising PSA Signals Recurrence

After surgery, the most widely used definition of biochemical recurrence has historically been a PSA that reaches 0.2 ng/mL or higher. But that threshold has been debated for years. Research comparing several candidate cutoffs found that the strongest association between a rising PSA and later spread of cancer occurred at a single reading of 0.4 ng/mL or higher. At that level, about three-quarters of men went on to experience a continued PSA increase over the following five years, and the association with eventual metastasis was strongest.⁹ A separate analysis reached a similar conclusion, finding that a PSA of 0.4 ng/mL followed by a further increase was the definition that best predicted distant metastasis.¹⁰

In practice, many doctors still use 0.2 ng/mL as an action threshold because waiting until 0.4 means missing a window for early salvage treatment. This tension between the best definition of true recurrence and the best moment to intervene explains why your urologist might recommend imaging or treatment even when your PSA is in that gray zone between 0.2 and 0.4 ng/mL.

Why Salvage Treatment Timing Matters

If your PSA rises after surgery and salvage radiation is being considered, the level at which you start that treatment affects outcomes. A study of men who received salvage radiation found that those treated when their PSA was above 0.25 ng/mL had roughly a 50% higher risk of dying compared to those treated at 0.25 or below. That elevated risk held for cutoffs up to 0.5 ng/mL but was not seen for cutoffs below 0.25.¹¹ The message is straightforward: if salvage treatment is on the table, earlier is generally better, and getting it while your PSA is still very low improves the odds that it works.

PSA Doubling Time Matters More Than a Single Number

A detectable PSA after treatment is not, by itself, a death sentence. What often matters more is how fast the number is climbing. PSA doubling time, the time it takes for the PSA level to double, gives your doctor a sense of how aggressive the remaining disease is.

Men with a doubling time under three months face the highest risk. One study found their risk of metastasis was more than five times that of men whose PSA doubled every ten to twelve months.¹² Earlier research showed that a rapid doubling time was nearly always associated with distant spread, while a slow doubling time correlated with local recurrence, which is more treatable.¹³ In a long-term analysis, patients with a doubling time of 15 months or longer were more likely to die of something other than prostate cancer entirely, while those with a doubling time under 15 months accounted for the vast majority of prostate cancer deaths.¹⁴

This is why your doctor tracks PSA over multiple readings rather than reacting to a single result. A slow, steady rise from 0.05 to 0.10 over two years carries very different implications from a jump from 0.05 to 0.40 in six months.

PSA That Is Not from Cancer

A low but detectable PSA after prostatectomy does not always mean cancer is back. There are two main non-cancer explanations worth knowing about.

First, small amounts of benign prostate tissue can be left behind during surgery, particularly near the junction where the urethra meets the bladder. This is actually a common pathology finding. Reassuringly, studies have shown that these leftover benign glands do not increase the risk of biochemical recurrence, detectable PSA, or disease progression.¹⁵ An earlier study reached the same conclusion: benign glands at the surgical margin were common but had no impact on disease outcome.¹⁶

Second, PSA is not actually unique to the prostate despite its name. Small quantities are produced by the trachea, thyroid, mammary gland, salivary glands, small intestine, and several other tissues. The concentrations in these tissues represent less than 1% of what the prostate produces, but ultrasensitive assays can pick up even these tiny amounts.¹⁷ Female breast tissue is actually the second richest source of PSA after the prostate, which is why PSA can even be detected in breast fluid and breast milk.¹⁸ For a man after prostatectomy, these non-prostatic sources can produce a faintly detectable reading on an ultrasensitive test without any cancer being present.

Lab-to-Lab Variability Can Shift Your Number

Even if nothing in your body has changed, switching labs or test platforms can make your PSA appear to rise or fall. A 2024 study comparing five commonly used PSA assay platforms found that total PSA values varied substantially between manufacturers, with results from one brand running about 21% lower than those from another, and a third brand reading nearly 10% higher.¹⁹ At the very low PSA levels relevant to post-treatment monitoring, this kind of variation can mean the difference between a result labeled “undetectable” and one that reads as just barely detectable. This is why most guidelines recommend sticking with the same lab and the same assay platform for all your follow-up tests. If you do switch labs, let your doctor know so the change in instrument is not mistaken for a change in your cancer status.

On rare occasions, the test itself produces a genuinely false result. Heterophilic antibodies, proteins in some patients’ blood that interfere with the assay chemistry, can cause a PSA test to read higher than the true value. At least one published case documented a man who received unnecessary additional treatment after radical prostatectomy because heterophilic antibodies in his blood caused falsely positive PSA results.²⁰ If your PSA pattern does not match your clinical picture, your doctor may order a repeat test on a different assay platform to check for interference.

Undetectable PSA During Hormone Therapy

For men on androgen deprivation therapy, the goal is typically to drive the PSA as low as possible. Reaching an undetectable nadir on hormone therapy is a strong prognostic sign. One study found that men whose PSA nadir remained between 0.01 and 0.2 ng/mL had about a five-fold higher risk of progressing to castration-resistant disease, developing metastases, and dying of prostate cancer compared to men who achieved a truly undetectable nadir. When the analysis was restricted to patients followed with ultrasensitive assays, the PSA nadir alone was highly accurate at predicting these outcomes.²¹

Medications That Can Artificially Lower PSA

If you take finasteride or dutasteride for an enlarged prostate or hair loss, your PSA will be artificially suppressed. These drugs, called 5-alpha reductase inhibitors, reduce PSA by roughly half after about a year of continuous use.²⁴ The suppression kicks in within about six months.²⁵ This means that a PSA reading that looks reassuringly low could actually be masking a higher underlying value. The standard clinical workaround is to double your measured PSA if you have been on one of these medications for more than six months. If your doctor does not know you are taking finasteride or dutasteride (including the lower doses sometimes prescribed for male-pattern baldness), your PSA results can be misinterpreted.

PSMA-PET Imaging at Very Low PSA Levels

When PSA starts to rise after treatment but is still very low, traditional imaging like CT scans and bone scans often cannot find where the cancer is. Newer PSMA-PET scans, which use a radioactive tracer that binds to prostate cancer cells, are far more sensitive. Even at PSA levels below 0.5 ng/mL, PSMA-PET scans can detect suspicious lesions. One study of patients scanned at very low PSA levels (below 0.5 ng/mL) found a detection rate of about 39%, which climbed to 55% in the 0.5 to 1.0 range and reached 100% above 1.0 ng/mL.²⁶ Another study reported the lowest PSA at which a positive scan occurred was just 0.02 ng/mL, a level well within the “barely detectable” range on an ultrasensitive assay.²⁷

The availability of PSMA-PET scanning has changed the clinical landscape in a meaningful way. Doctors can now locate recurrent disease at PSA levels that would have been considered too low to investigate a decade ago. This in turn supports the trend toward earlier salvage treatment, because you can direct radiation or other therapy at a known target rather than treating blindly.

The Emotional Weight of PSA Monitoring

Waiting for a PSA result every few months, sometimes for years or even decades, takes a psychological toll that does not get discussed enough. A systematic review on the topic identified PSA anxiety as a distinct and recurring problem among prostate cancer patients, describing it as physical or emotional distress tied to PSA testing and elevated levels. Higher PSA readings drove higher anxiety, and the pattern was closely intertwined with a broader fear of cancer recurrence.²⁸ Some men describe the days before and after a blood draw as among the most stressful of their lives, regardless of how many previous results came back undetectable.

If you find that PSA testing triggers significant anxiety, it is worth raising with your care team. Some clinics schedule the blood draw and the results discussion on the same day to shorten the wait. Understanding what your particular threshold means, and that a single barely detectable result is not the same as aggressive recurrence, can also help put individual readings in context. Your doctors are looking at the trajectory across multiple results, not reacting to a single data point in isolation.